Roche and Flatiron Health, Inc. have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6 percent. The transaction is expected to close in the first half of 2018. Flatiron Health, a privately held healthcare technology and services company headquartered in New York…
Roche Assay Okayed to Assist Novartis Drug in Lung Cancer Detection
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients. Roche announced U.S. Food and Drug Administration (FDA) approval of the Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug Zykadia (ceritinib). The Ventana ALK (D5F3) Assay is…
Roche Reports a Good Start in 2017
Roche’s Perjeta Meets Primary Endpoint in Breast Cancer Study
Roche Reports Positive 2016 Results, Sees More Growth in 2017
Roche reports good results in 2016. Group sales increase 4%1 at constant exchange rates, 5% in Swiss francs (CHF) Pharmaceuticals division sales up 3%, mainly driven by cancer medicines Perjeta and Herceptin as well as Actemra/RoActemra Diagnostics division sales grow 7%, driven primarily by immunodiagnostic solutions Successful launches of four new medicines; five U.S. FDA breakthrough therapy…